Researchers Report Stem Cell Alternative: related news

Hot nanotube sheets produce music on demand

Energy & Fuels Special Report Brain Special Report Stem Cells Special Report Comets & Asteroids Special Report Cancer Special Report Climate Change Special Report Nanotechnology Special Report Bird Flu Special Report Drugs & Alcohol Special Report Astrobiology Special Report GM Organisms Special Report Love Special Report Genetics Special Report Nuclear Special Report HIV Special Report Robots Special Report Evolution Special Report Quantum World Special Report

Major Stem Cell Breakthrough

(Nanowerk News) Minerva Biotechnologies, a leading nanotechnology, cancer and stem cell development company today announced a major breakthrough in stem cell research. Minerva and collaborators at the University of California at Santa Barbara discovered that a single, new growth factor can not only support massive growth of human embryonic stem cells (hESCs) in vitro, but also maintains them in a nearly 100% undifferentiated state without the need for fibroblast "feeder cells". This represents a major step forward for potential stem cell therapies as well as in the basic understanding of the mechanisms that regulate stem cell growth and differentiation.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

CAMBRIDGE, England, November 14 /PRNewswire-FirstCall/ -- - European IRES Patent Upheld and UK Patent on Cell Screening Technology Granted - ("Stem Cell Sciences", "SCS", "the Company") IRES Patent Upheld in Appeal Hearing at the EPO Stem Cell Sciences plc

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

CAMBRIDGE, England, November 14, 2008 /PRNewswire-FirstCall/ --Stem Cell Sciences plc announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Researchers Expect Hackers To Prey on Cell Phones

Now security researchers say cell phones, and not just PCs, are the next likely conscripts into the automated armies. The mobile phone as zombie computer is one possibility envisioned by security researchers from Georgia Tech in a new report coming out Wednesday. The report identifies the growing power of cell phones to open a new avenue of attack for hackers. Of particular concern is that as cell phones get more computing power and better Internet connections, hackers can capitalize on vulnerabilities in mobile-phone operating systems or Web applications. Botnets, or networks of infected or robot PCs, are the weapons of choice when it comes to spam and so-called “denial of service attacks,” in which computer servers are overwhelmed with Internet traffic to shut them down.

Researchers Report Stem Cell Alternative

Scientists say they might have found an alternative to embryonic stem cells that would allow them to exit an ethics debate over using discarded embryos.

Researchers report stem cell alternative

Scientists say they might have found an alternative to embryonic stem cells that would allow them to exit an ethics debate over using discarded embryos.

Researchers report stem cell alternative

CAMBRIDGE, Mass., Sept. 27 (UPI) -- Scientists say they might have found an alternative to embryonic stem cells that would allow them to exit an ethics debate over using discarded embryos.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in

Pharmicell to Bring Stem Cell Therapy to European Market

Pharmicell received the official authorization for production of somatic cell therapeutics derived from adipose tissue. The license allows to produce and to market adipose tissue derived stem cells in Europe. With this permit, Pharmicell can provide its cell product (Twelve Cell SolutionTM) for a wide range of plastic-aesthetic therapies such as wrinkle and skin treatments, breast augmentation, and breast reconstruction after breast cancer surgery and radiation. According to the company, Pharmicell is the first in Europe to provide GMP-certified fat cell products for clinical uses. Pharmicell has completed LOIs with Clinica Vita and Charité to introduce its products. The fat cell service will be available to German customers immediately.

Time Of Day Influences Yield For Pharmacologically Stimulated Stem Cell Mobilization

A new study uncovers a previously unrecognized, species-specific impact of circadian rhythms on the production of mobilized stem cells. The research, published by Cell Press in the October 9th issue of the journal Cell Stem Cell, suggests that when it comes to collecting human stem cells for clinical transplantation, picking the right time of day to harvest cells may result in a greater yield.

Time of day influences yield for pharmacologically stimulated stem cell mobilization

A new study uncovers a previously unrecognized, species-specific impact of circadian rhythms on the production of mobilized stem cells. The research, published by Cell Press in the October 9th issue of the journal Cell Stem Cell, suggests that when it comes to collecting human stem cells for clinical transplantation, picking the right time of day to harvest cells may result in a greater yield.

Muscle Stem Cell Identity Confirmed By Researchers

A single cell can repopulate damaged skeletal muscle in mice, say scientists at the Stanford University School of Medicine, who devised a way to track the cell's fate in living animals. The research is the first to confirm that so-called satellite cells encircling muscle fibers harbor an elusive muscle stem cell.

Stem Cell Therapeutics Announces Issuance of Australian Patent

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) has been issued Australian Patent No. 2003250697, entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells". This patent, issued on August 14, 2008, covers methods of producing oligodendrocytes from neural stem cells using granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5 (IL-5), either in vivo or in cell culture, as well as oligodendrocyte compositions produced by such methods. This is the first patent to issue in this patent family.

Stem Cell Therapeutics Announces Issuance of Australian Patent

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) has been issued Australian Patent No. 2003250697, entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells". This patent, issued on August 14, 2008, covers methods of producing oligodendrocytes from neural stem cells using granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5 (IL-5), either in vivo or in cell culture, as well as oligodendrocyte compositions produced by such methods. This is the first patent to issue in this patent family.

Feds Can Locate Cell Phones Without Telcos

schwit1 sends along an Ars Technica report covering the release of documents obtained under the FOIA suggesting that the Justice Department may have been evading privacy laws in their use of "triggerfish" technology. Triggerfish are cell-tower spoofing devices that induce cell phones to give up their location and other identifying information, without recourse to any cell carrier. "Courts in recent years have been raising the evidentiary bar law enforcement agents must meet in order to obtain historical cell phone records that reveal information about a target's location. But documents obtained by civil liberties groups under a Freedom of Information Act request suggest that 'triggerfish' technology can be used to pinpoint cell phones without involving cell phone providers at all.

Stem cell supporters await their Obama moment

WASHINGTON (Reuters) - Stem cell advocates and researchers are eagerly awaiting the moment next year when president-elect Barack Obama rescinds a directive that limits federal funding of human embryonic stem-cell research.

A breakthrough, then a surge, in stem cell research

Less than a year after a Wisconsin team helped discover a major alternative to human embryonic stem cells, the Madison scientists say more than 800 labs have begun using the approach, suggesting that many stem-cell researchers are starting to move beyond controversial embryonic sources for their work.

RNCOS Releases a New Report- European Mobile Market Scenario to 2012

(EMAILWIRE.COM, October 26, 2008 ) New Delhi, India - RNCOS has recently added a new Market Research Report titled, “European Mobile Market Scenario to 2012” to its report gallery. The report is an extensively researched objective analysis on the growing marketplace for mobile handset industry in the Europe. The report discusses the impact of technology on the mobile market and anticipates the future direction of key segments of the market. This report will help the clients to analyze the leading-edge opportunities critical to the success of the growing mobile handset market in Europe. The analysis given in the report is supplemented with the statistical facts and helps handset manufacturers, service providers, and investors navigate the evolving market of mobile handsets in Europe.

Forsyth scientists trigger cancer-like response from embryonic stem cells

Scientists from The Forsyth Institute, working with collaborators at Tufts and Tuebingen Universities, have discovered a new control over embryonic stem cells' behavior. The researchers disrupted a natural bioelectrical mechanism within frog embryonic stem cells and trigged a cancer-like response, including increased cell growth, change in cell shape, and invasion of the major body organs. This research shows that electrical signals are a powerful control mechanism that can be used to modulate cell behavior.

Forsyth scientists trigger cancer-like response from embryonic stem cells

Boston--Scientists from The Forsyth Institute, working with collaborators at Tufts and Tuebingen Universities, have discovered a new control over embryonic stem cells' behavior. The researchers disrupted a natural bioelectrical mechanism within frog embryonic stem cells and trigged a cancer-like response, including increased cell growth, change in cell shape, and invasion of the major body organs. This research shows that electrical signals are a powerful control mechanism that can be used to modulate cell behavior.

Researchers Report Stem Cell Advance (HealthDay)

A team of Boston scientists developed a way to generate induced pluripotent stem cells (iPS) -- which are functionally similar to

Search took 0.34 seconds.